Programme 2022

Preliminary Programme

Conference Day 1
Thursday, 7 April 2022

Conference Day 2
Friday, 8 April 2022

Conference Day 1

Thursday, 7 April 2022

09:00 – 11:00

Pre-conference Meeting

Meeting BEAM Alliance (for members only)

 
// for BEAM members only //

11:00 – 11:30

Networking Break

11:30 – 13:00

Pre-conference workshops & site meetings

IMI AMR Accelerator Communication Advisory Board Meeting (details tbd, by invitation only)

Workshop with a Focus on drug development financed by Novo Repair Impact Fund (details tbd)

Networking event by AntiResist (by invitation only) 

13:00 – 21:30

Registration, poster presentations and exhibition open

13:00 – 14:00

Lunch Break

14:00 – 15:30

Opening | Keynote | Plenary talk

AMR innovation: Finally on track to market & patients?

15:30 – 16:00

Coffee Break with poster session & exhibition

15:30 – 20:30

1-to-1 Partnering Meetings

16:00 – 17:30

Parallel Tracks

A new era for TB drug development: From innovation trial design to efficient drug regiments

Hosted by the IMI AMR Accelerator & in cooperation with the Unite4TB/Era4TB consortia

Diagnostics in AMR: Focus on market needs & learnings from innovative COVID-19 approaches

 

Impact of pull incentives on the R&D portfolio: Current status & perspectives

17:30 – 18:00

Coffee Break with poster session & exhibition

18:00 – 19:30

Plenary session

Start-up pitches @AMR Conference

Panel talk with investors & funders

hosted by INCATE

Further partners include:

             

19:30 – 21:30

Joint reception & Dinner in the exhibition hall

Conference Day 2

Friday, 8 April 2022

08:00 – 18:30

Registration, poster presentations and exhibition open

08:30 – 10:00

Parallel Tracks

Animal infection models & other tools for preclinical efficiency

in cooperation with IMI AMR Accelerator & further partners

Novel approaches in AB Discovery & new technologies

in cooperation with the NCCR AntiResist network

Focus on One Health

hosted by the Global AMR Hub

10:00 – 10:45

Coffee Break with poster session & exhibition

10:00 – 16:30

1-to-1 Partnering Meetings

10:45 – 12:00

Plenary Session

What’s next on the global policy agenda for AMR?

12:00 – 13:30

Lunch Break with poster session, round tables & exhibition

13:30 – 14:30

Parallel Tracks

The challenge of clinical development: Trial design & regulatory perspectives

Vaccines back on track to combat AMR: New approaches & challenges

Focus on diagnostic technologies

in cooperation with

14:30 – 15:00

Networking Break

15:00 – 16:00

Parallel Tracks

Focus on clinical needs: Which innovation in AMR is in demand?

in cooperation with WHO

Focus on therapeutic programmes from early to late stage

(company presentations)

Focus on fungal infections: Current trends & lessons learned for the fight against AMR

16:00 – 16:30

Coffee Break with poster session & exhibition

16:30 – 17:30

Plenary session

Cooperate & accelerate: How to speed up AMR innovation & next challenges ahead

17:30 – 18:30

Closing reception

BEAM Alliance programme committee

Marc Gitzinger

CEO, BioVersys AG, CH & Vice President Board, BEAM Alliance

Marc Lemonnier

Founding CEO, Antabio SAS

Deborah O’Neil

CEO, NovaBiotics Ltd & Board Member, BEAM Alliance